





CLINICAL PRACTICE GUIDELINE

Therapeutics and COVID-19—A living WHO guideline: Endorsement by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine

Morten H. Møller¹  | Michelle S. Chew² | Klaus T. Olkkola³ | Marius Rehn^{4,5,6}  | Arvi Yli-Hankala^{7,8}  | Martin I. Sigurðsson^{9,10} 

¹Department of Intensive Care, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

²Department of Anaesthesia and Intensive Care, Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

³Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

⁴Division of Prehospital Services, Air Ambulance Department, Oslo University Hospital, Oslo, Norway

⁵The Norwegian Air Ambulance Foundation, Drøbak, Norway

⁶Faculty of Health Sciences, University of Stavanger, Stavanger, Norway

⁷Department of Anaesthesia, Tampere University Hospital, Tampere, Finland

⁸Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

⁹Division of Anesthesia and Intensive Care Medicine, Landspítali-The National University Hospital of Iceland, Reykjavik, Iceland

¹⁰Faculty of Medicine, University of Iceland, Reykjavik, Iceland

Correspondence

Morten Hylander Møller, Department of Intensive Care, Copenhagen University Hospital Rigshospitalet, DK-2100 Copenhagen, Denmark.
Email: mortenhylander@gmail.com

Funding information

Funding was provided from the Scandinavian Society of Anaesthesiology and Intensive Care Medicine and institutional and/or departmental sources.

Abstract

The Clinical Practice Committee of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine endorses the *Living WHO guideline on therapeutics and COVID-19*. This trustworthy continuously updated guideline serves as a highly useful decision aid for Nordic anaesthesiologists caring for patients with COVID-19.

KEYWORDS

AGREE II, clinical practice guideline, COVID-19, therapeutics, WHO

1 | BACKGROUND

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a pandemic of coronavirus disease 2019 (COVID-19),¹ including in the Nordic countries.² Many patients have suffered from severe hypoxic respiratory failure and have died, and most healthcare systems worldwide have been overwhelmed by the surge of patients needing hospitalisation and intensive care.^{3,4}

The *World Health Organization (WHO) living guideline on therapeutics in COVID-19* continuously summarises the emerging evidence

from randomised controlled trials on existing and new drug treatments for COVID-19.⁵

2 | METHODS

It was decided by the Clinical practice committee (CPC) of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine (SSAI) to assess the 7th edition of the *Living WHO guideline on therapeutics and COVID-19*⁵ for possible endorsement. The Appraisal of Guidelines for REsearch and Evaluation (AGREE) II

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *Acta Anaesthesiologica Scandinavica* published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.

tool⁶ was used. Details on the endorsement process are available elsewhere.⁷

3 | RESULTS

All six SSAI CPC members completed the appraisal. The individual domain totals were: Scope and Purpose 94%; Stakeholder Involvement 84%; Rigour of Development 94%; Clarity of Presentation 91%; Applicability 83%; Editorial Independence 76%; Overall Assessment 94% (Figure 1).

The breakdown of the individual appraisers (de-identified) is available in the Supporting information.

4 | DISCUSSION

Agreement between the SSAI CPC appraisers was high and the overall assessment of the guideline was very good. The guideline can be used in daily clinical practice in Nordic countries without adaptation or modification. Of note, the effects of the proposed therapeutic agents may to some extent be sensitive to the specific settings they are used in, including the baseline disease severity of COVID-19.

The *Living WHO guideline on therapeutics and COVID-19*⁵ serves as a highly useful decision aid for Nordic anaesthesiologists caring for patients with COVID-19. Detailed recommendations, evidence

summaries, and decision aids are available in MAGICapp (<https://app.magicapp.org/#/guideline/nBkO1E>).

5 | CONCLUSION

The SSAI CPC endorses the *Living WHO guideline on therapeutics and COVID-19*.⁵

CONFLICTS OF INTEREST

No Clinical Practice Committee member had direct or indirect conflicts of interest.

ORCID

Morten H. Møller  <https://orcid.org/0000-0002-6378-9673>

Marius Rehn  <https://orcid.org/0000-0001-9519-241X>

Arvi Yli-Hankala  <https://orcid.org/0000-0002-5029-9181>

Martin I. Sigurðsson  <https://orcid.org/0000-0001-7054-0844>

REFERENCES

1. JHU. Center for Systems Science and Engineering at Johns Hopkins University. Coronavirus COVID-19 Global Cases [Internet]. Available from: <https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>
2. Chew MS, Kattainen S, Haase N, et al. A descriptive study of the surge response and outcomes of ICU patients with COVID-19 during first wave in Nordic countries. *Acta Anaesthesiol Scand*. 2022;66:56-64.
3. Aziz S, Arabi YM, Alhazzani W, et al. Managing ICU surge during the COVID-19 crisis: rapid guidelines. *Intensive Care Med* 2020;46:1303-1325. doi: [10.1007/s00134-020-06092-5](https://doi.org/10.1007/s00134-020-06092-5)
4. WHO. WHO Coronavirus (COVID-19) Dashboard [Internet]. Available from: <https://covid19.WHO.int/>
5. Lamontagne F, Agoritsas T, MacDonald H, et al. A living WHO guideline on drugs for covid-19. *BMJ*. 2020;370: m3379.
6. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. *J Clin Epidemiol*. 2010;63:1308-1311.
7. Rehn M, Chew MS, Olkkola KT, Örn Sverrisson K, Yli-Hankala A, Møller MH. Endorsement of clinical practice guidelines by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. *Acta Anaesthesiol Scand*. 2019;63:161-163.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.




FIGURE 1 Summary of the Appraisal of Guidelines for REsearch and Evaluation (AGREE) II assessment⁶[Colour figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

How to cite this article: Møller MH, Chew MS, Olkkola KT, Rehn M, Yli-Hankala A, Sigurðsson MI. Therapeutics and COVID-19—A living WHO guideline: Endorsement by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine. *Acta Anaesthesiol Scand*. 2022;66:636–637. <https://doi.org/10.1111/aas.14046>